Asahi Kasei Medical to acquire US-based CDMO Bionova Scientific
Asahi plans to use the CDMO to propel its bioprocess business
Asahi Kasei Medical has closed an agreement to acquire Bionova Scientific, a US-based provider of contract process development services and GMP-compliant contract manufacturing services to biopharmaceutical companies.
Asahi Kasei Medical is the arm of Asahi Kasei Group best known for its sale of Planova filters and bioprocess equipment. It has been expanding in recent years into the field of biosafety contract testing with the 2019 acquisition of Austrian viral safety testing services provider Virusure Forschung und Entwicklung GmbH, followed by the 2021 acquisition of US-based Bionique Testing Laboratories.
Bionova Scientific is known for its highly-regarded process development capabilities, particularly in the area of complex next-generation antibody drugs, which are typically challenging to manufacture.
Its GMP manufacturing facility, located in California, has state-of-the-art equipment including single-use bioreactors, suited to meet rising demand driven by the expansion of the antibody drug market and a steep increase in the number of biopharmaceuticals entering the clinical pipeline.
Asahi Kasei Medical says it will use the acquisition of Bionova to propel its bioprocess business.
Ken Shinomiya, Director at Asahi Kasei Medical, commented that the company is ‘thrilled’ to announce the acquisition.
‘After an in-depth evaluation of Bionova and other biologics CDMOs, we are extremely impressed with Bionova’s scientific strength, their best-in-class facility and their passionate team that is both highly technically capable and extremely attentive to customer needs. They are the ideal organization to serve as the foundation for our entry into the biopharmaceutical CDMO services business,’ he said.
Bionova Scientific CEO Darren Head added, ‘We are extremely excited to become a part of Asahi Kasei. This represents an important step in our evolution as a company and provides access to new resources that will enable us to continue to add to our capacity and capabilities.’
Closing of the acquisition is subject to receipt of necessary regulatory clearances.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance